Needham initiated coverage on Enovis Corporation with a new price target
$ENOV
Industrial Specialties
Health Care
Needham initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $70.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/3/2024 | $62.00 | Mkt Outperform | JMP Securities |
| 6/13/2024 | $53.00 | Neutral | JP Morgan |
| 2/13/2024 | $72.00 | Overweight | Stephens |
| 1/22/2024 | $75.00 | Buy | UBS |
| 1/3/2024 | Outperform | William Blair | |
| 12/15/2023 | $62.00 → $70.00 | Buy | Needham |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
| 6/26/2023 | $70.00 | Buy | Needham |
Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity Musculoskeletal Conference: Ben Berry, Chief Financial Officer, and Louie Vogt, Group President - Recon, will participate in a fireside chat on Monday, March 10th at 10:00 a.m. Pacific Time.37th Annual Roth Conference: Louie Vogt, Group President - Recon, will participate in a fireside chat on Monday, March 17th at 8:30 a.m. Pacific Time.24th Annual Needham Healthcarte Conference: Ben Berry, Chief Financial Officer, will participate in
Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the "Board") of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company's next CEO. Upon th
NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index
WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the "Board") of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company's next CEO. Upon th
Wilmington, DE, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on Wednesday, February 26th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call as well as a webcast can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, ple
JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00
JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00
Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
10-K - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)